Microtherapeutics Is On The Mend

With the recent swirl of takeovers in the medical devices industry, MicroTherapeutics (MTIX) is gaining new fans. "It represents the only public pure play in the more than $1 billion neurovascular intervention market," says Sam Navarro, managing director at ING Baring Furman Selz. He notes that a number of companies have expressed an interest in MicroTherapeutics, which makes micro-catheters and micro-guidewires for the treatment of vascular ailments such as blood clots.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.